Inhibitory effects of icotinib combined with antiangiogenic drugs in human non‐small cell lung cancer xenograft models are better than single target drugs-Reference-Cited by-同舟云学术

Inhibitory effects of icotinib combined with antiangiogenic drugs in human non‐small cell lung cancer xenograft models are better than single target drugs

Published:2021-12-02 Issue:2 Volume:13 Page:257-264
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Jiang Peng¹²,Zhang Yan³,Cui Jiadong⁴,Wang Xiuxiu¹,Li Yu¹^ORCID

Affiliation:

1. Department of Pulmonary and Critical Care Medicine, Qilu Hospital, Cheeloo College of Medicine Shandong University Jinan China

2. Department of Pulmonary and Critical Care Medicine Weihai Municipal Hospital Weihai China

3. The Fourth People's Hospital of Jinan Jinan China

4. Department of Pulmonary Medicine Dong'e County People's Hospital Liaocheng China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14261

Reference32 articles.

1. The Global Burden of Pulmonary Diseases: Most Prevalent Problems and Opportunities for Improvement

2. Non-small cell lung cancer: current treatment and future advances

3. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

4. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors;Journal of Cancer Research and Clinical Oncology;2024-04-30

2. Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non–small cell lung cancer patients;Investigational New Drugs;2023-05-04

3. PATIENTS WITH EGFR-MUTATED LUNG ADENOCARCINOMA AFTER PROGRESSION;ACTA MEDICA MEDITERR;2023